Early Alzheimer's Screening (HCEAD01)
With the continuous aging of the population, the number of individuals with dementia is steadily increasing, becoming a significant public health issue in society. The rise in dementia cases places a heavy burden on care and medical resources, while also subjecting patients and their families to prolonged physical and psychological stress.
Early detection is crucial, enabling timely treatment to slow cognitive decline, maintain quality of life and dignity, and reduce caregiver burden.
What is the relationship between dementia and Alzheimer's disease?
Alzheimer's disease is the most common type of dementia, accounting for up to 74% of dementia cases¹. In Alzheimer's patients, excessive accumulation of abnormal proteins in the brain disrupts communication between nerve cells, leading to nerve cell death and brain atrophy.
What are the advantages of early detection?
If the disease is detected in its early stages, lifestyle and environmental changes, combined with treatment, can slow disease progression. Therefore, it is crucial not to miss the golden treatment window.
Early Alzheimer’s Screening Principle:
A simple blood draw is all that is needed to accurately measure the level of phosphorylated Tau217 protein (p-Tau217) in the blood, a biomarker associated with Alzheimer's disease (AD) pathology, to assess the risk of AD. Multiple studies have shown that the results of the p-Tau217 blood test closely correlate with those from traditional PET-CT scans and cerebrospinal fluid biomarkers.
Reference:
¹ Hong Kong Jockey Club Charities Trust. The Jockey Club "Smart Health" Dementia Screening and Community Support Program Establishes Primary Care Services for Dementia [Press release]. Faculty of Medicine, The Chinese University of Hong Kong. https://www.jccpa.org.hk/wp-content/uploads/2024/09/20240916_DSCS_EC-Screen-Data-Analysis-Press-Release_C_FINAL.pdf
² Hospital Authority-SMAR PATIEN. “How Common is Dementia?"
1) Collection of blood samples
2) Analysis at the laboratory
3) Report Interpretation and conclusive advice by medical professional
• Age 50 or above
• Family history of Alzheimer's disease (AD)
• Patients with hypertension, diabetes, or hyperlipidemia
• Individuals suspected of mild cognitive impairment
Services include:
‧Analysis and assessment of Alzheimer's disease risk levels
Additional items:
‧Report interpretation and conclusive advice by medical professional
Designated Health Check Centre Address:
Tsim Sha Tsui- Impact Medical Imaging Centre
Shop 102B, 1/F, Star House, 3 Salisbury Road, Tsim Sha Tsui, Kowloon
Mong Kok- Impact Medical Imaging Centre
Room 712, 7/F , Office Tower One , Grand Plaza, 625 & 639 Nathan Road, Mong Kok, Kowloon
• Human Health will contact the customer within 2 working days after successful payment. Customers can also make a reservation by calling the hotline at +852 2397 2111 during office hours.
• The physical check-up plan is available at designated Human Health Check-up Centre- Impact Medical Imaging Centre.
• Customers must present their identity cards and order confirmation letter (printed or e-version) on the appointment day.
•Check-up plan is applicable to people aged 18 or above only.
•Check-up plan is not applicable on Sundays and Public Holidays.
• The redemption will be valid for 6 months starting from the date of payment.
• Neither amendment nor cancellation is allowed once the payment has been confirmed. Also, it is not transferable nor refundable.
• All tests are not for the purpose of medical diagnosis or treatment.
• Offers cannot be used in conjunction with any other promotional offers or discounts and cannot be exchanged for cash or other products.
• In case of disputes, the decision of Human Health shall be final.